Diamyd Medical AB (FRA:DMN) E10: €-0.07 (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:DMN Diamyd Medical AB FRA:DMN
41 GF Score
Price €0.07
GF Value €0.07
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Diamyd Medical AB E10?

Diamyd Medical AB FRA:DMN -3.97% 41 E10 is €-0.07 as of May. 2026. GuruFocus rates FRA:DMN with a GF Score™ of 41/100 and a GF Value™ of €0.07 (Fairly Valued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Diamyd Medical AB's adjusted earnings per share data for the three months ended in May. 2026 was €-0.074. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-0.07 for the trailing ten years ended in May. 2026.

During the past 3 years, the average E10 Growth Rate was 4.30% per year. During the past 5 years, the average E10 Growth Rate was -1.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Diamyd Medical AB was 4.30% per year. The lowest was -1.30% per year. And the median was 3.20% per year.

As of today (2026-08-10), Diamyd Medical AB's current stock price is €0.0725. Diamyd Medical AB's E10 for the quarter that ended in May. 2026 was €-0.07. Diamyd Medical AB's Shiller PE Ratio of today is .


Diamyd Medical AB  (FRA:DMN) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Diamyd Medical AB E10 Related Terms


Diamyd Medical AB E10 Historical Data

* Premium members only.

The historical data trend for Diamyd Medical AB's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diamyd Medical AB E10 Chart

Diamyd Medical AB Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.09 -0.10 -0.06 -0.07 -0.08

Diamyd Medical AB Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.08 -0.08 -0.08 -0.09 -0.07

FRA:DMN vs VRTX, REGN, RVMD: E10 Comparison

For the Biotechnology subindustry, Diamyd Medical AB's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Diamyd Medical AB Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Diamyd Medical AB's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Diamyd Medical AB's Shiller PE Ratio falls into.


FRA:DMN
41GF Score
Diamyd Medical AB FRA:DMN
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Diamyd Medical AB E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Diamyd Medical AB's adjusted earnings per share data for the three months ended in May. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of May. 2026 (Change)*Current CPI (May. 2026)
=-0.074/134.1100*134.1100
=-0.074

Current CPI (May. 2026) = 134.1100.

Diamyd Medical AB Quarterly Data

per share eps CPI Adj_EPS
201608 -0.015 100.968 -0.020
201611 -0.010 101.517 -0.013
201702 -0.018 102.037 -0.024
201705 -0.030 102.679 -0.039
201708 -0.010 103.138 -0.013
201711 -0.020 103.413 -0.026
201802 -0.020 103.678 -0.026
201805 -0.019 104.632 -0.024
201808 -0.019 105.197 -0.024
201811 -0.019 105.443 -0.024
201902 -0.019 105.641 -0.024
201905 -0.009 106.895 -0.011
201908 -0.013 106.716 -0.016
201911 -0.009 107.345 -0.011
202002 0.046 106.742 0.058
202005 -0.009 106.882 -0.011
202008 -0.019 107.571 -0.024
202011 0.142 107.549 0.177
202102 0.019 108.190 0.024
202105 -0.048 108.838 -0.059
202108 -0.038 109.780 -0.046
202111 -0.048 111.069 -0.058
202202 -0.009 112.834 -0.011
202205 -0.019 116.746 -0.022
202208 -0.055 120.573 -0.061
202211 -0.036 123.803 -0.039
202302 -0.026 126.321 -0.028
202305 -0.026 128.034 -0.027
202308 -0.044 129.560 -0.046
202311 -0.034 130.958 -0.035
202402 -0.027 132.046 -0.027
202405 -0.034 132.818 -0.034
202408 -0.044 132.052 -0.045
202411 -0.034 133.000 -0.034
202502 -0.035 133.744 -0.035
202505 -0.037 133.064 -0.037
202508 -0.027 133.440 -0.027
202511 -0.036 133.340 -0.036
202602 -0.028 134.410 -0.028
202605 -0.074 134.110 -0.074

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-0.07 mean?
Diamyd Medical AB (FRA:DMN) has a E10 of €-0.07 as of May. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Diamyd Medical AB and its competitors.
Is Diamyd Medical AB's E10 too high?
Diamyd Medical AB's current E10 is €-0.07. Overall, Diamyd Medical AB has a GF Score™ of 41/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Diamyd Medical AB's E10 compare to VRTX and REGN?
Diamyd Medical AB's E10 of €-0.07 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Diamyd Medical AB and its competitors. Diamyd Medical AB's current E10 is €-0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diamyd Medical AB stock overvalued right now?
Based on GuruFocus' analysis, Diamyd Medical AB (FRA:DMN) is currently considered Fairly Valued. The stock's GF Value™ is €0.07, compared to a current price of €0.07 — trading 3.6% above its estimated fair value. The current E10 is €-0.07. Diamyd Medical AB's overall GF Score™ is 41/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Diamyd Medical AB (FRA:DMN), the current E10 is €-0.07 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Diamyd Medical AB (FRA:DMN) Overvalued in 2026?

Based on GuruFocus' analysis, Diamyd Medical AB stock appears to be overvalued. The current stock price of €0.07 is trading 3.6% above its estimated GF Value™ of €0.07. GuruFocus considers Diamyd Medical AB to be Fairly Valued.

Key valuation signals for FRA:DMN:

  • E10: €-0.07
  • GF Value™: €0.07 vs. price of €0.07 (3.6% above fair value)
  • GF Score™: 41/100 with 3 warning signs

No single metric tells the full story. See the FRA:DMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Diamyd Medical AB Business Description

Other Exchanges DMYD B:Sweden
Address Kungsgatan 29, Stockholm, SWE, SE-111 56
Diamyd Medical AB develops precision medicine therapies for the prevention and treatment of type 1 diabetes using antigen-based immune technology. Its product candidate, Diamyd (rhGAD65/alum), is an antigen-specific immunomodulatory therapy that aims to preserve endogenous insulin production in individuals carrying the HLA DR3-DQ2 genotype and is being evaluated in the registrational Phase 3 DIAGNODE-3 trial in Stage 3 type 1 diabetes, as well as in the DiaPrecise trial in children with Stage 1 and Stage 2 type 1 diabetes. The Company's activities include clinical development, antigen-specific immunotherapy and in-house manufacturing of recombinant GAD65.
41GF Score

Get the complete analysis for FRA:DMN

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.07
Price
€0.07
GF Value